Form 4: 10x Genomics Executive Benjamin J. Hindson Reports Acquisition of Restricted Stock Units

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, reports the acquisition of restricted stock units representing a contingent right to receive Class A Common Stock.

Summary

• On March 17, 2025, Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, acquired 120,535 restricted stock units (RSUs).
• These RSUs represent a contingent right to receive one share of Class A Common Stock upon vesting.
• Vesting occurs in 1/12th increments on each quarterly anniversary from February 21, 2025, contingent upon continued service.
• Following the transaction, Hindson directly owns 455,859 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (RSU grant) and suggests continued alignment between the executive and the company's long-term success. It's a neutral-to-slightly positive indicator.

Positives

• The acquisition of RSUs by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the RSUs suggests a continued commitment from the executive to the company over the coming years.

Industry Context

Executive compensation in the form of stock options and RSUs is a common practice in the biotech industry to align management's interests with those of shareholders.

Stakeholder Impact

• The RSU grant aligns the executive's interests with those of shareholders, potentially driving long-term value creation.

Key Dates

Keywords

10x Genomics, TXG, Benjamin J. Hindson, Restricted Stock Units, RSUs, Class A Common Stock, Beneficial Ownership, Form 4, SEC Filing